nyxthracis (previously obiltoxaximab sfl)
sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - imunski sera in imunoglobulini, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.
docetaksel strides arcolab international 40 mg/ml koncentrat in vehikel za raztopino za raztopino za infundiranje
strides arcolab international limited - docetaksel - koncentrat in vehikel za raztopino za infundiranje - docetaksel 40 mg / 1 ml - docetaksel
docetaksel strides arcolab international 40 mg/ml koncentrat in vehikel za raztopino za raztopino za infundiranje
strides arcolab international limited - docetaksel - koncentrat in vehikel za raztopino za infundiranje - docetaksel 40 mg / 1 ml - docetaksel
ropinirol mylan 1 mg filmsko obložene tablete
filmsko obložena tableta - ropinirol
ropinirol mylan 1 mg filmsko obložene tablete
filmsko obložena tableta - ropinirol
ropinirol mylan 2 mg filmsko obložene tablete
filmsko obložena tableta - ropinirol
ropinirol mylan 2 mg filmsko obložene tablete
filmsko obložena tableta - ropinirol
ropinirol mylan 5 mg filmsko obložene tablete
filmsko obložena tableta - ropinirol
ropinirol mylan 5 mg filmsko obložene tablete
filmsko obložena tableta - ropinirol
esbriet
roche registration gmbh - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunosupresivi - esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.